XSHG
600750
Market cap2.22bUSD
Jul 10, Last price
23.53CNY
1D
-0.72%
1Q
-9.36%
Jan 2017
60.33%
Name
Jiang Zhong Pharmaceutical Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
China Resources Jiangzhong Pharmaceutical Co.,Ltd functions as a prominent Chinese manufacturer of a wide array of pharmaceutical products for the domestic market. Its extensive product portfolio includes a variety of over-the-counter (OTC) medications, such as tablets designed for stomach-strengthening and digestion promotion, lactobacillus tablets, and triple live bifidobacterium enteric-coated capsules. Other significant OTC offerings feature compound fresh bamboo juice liquid, compound coral lozenges, multivitamin tablets, Fritillaria and loquat capsules, bezoar and snake gallbladder Fritillaria liquid, and compound gold melon seed. Beyond pharmaceutical drugs, the company also provides health consumer goods. These range from general nourishing products and rehabilitation nutrition items to specialized solutions for gastrointestinal and liver health. Furthermore, China Resources Jiangzhong Pharmaceutical manufactures prescription drugs. This segment encompasses a broad selection of Traditional Chinese Medicine (TCM) products, including Shenbao capsules, Paishi granules, Huangba Shengmai drink, Bazhen Yimu capsules, Zhenju Jiangya tablets, Shuangju granules, Zhikang tablets, and Shuxiong granules. It also produces chemical medications such as lumbrokinase enteric-coated capsules, Rabelagat sodium enteric-coated tablets, and chloroprocaine hydrochloride. Additionally, the company processes and supplies essential medicinal raw materials, including stir-fried Chinese jujube seeds, French pinellia, and vinegar-soaked northern bupleurum. The company, headquartered in Nanchang, China, was established in 1996. It was formerly identified as Jiang Zhong Pharmaceutical Co.,Ltd before officially adopting its current name, China Resources Jiangzhong Pharmaceutical Co.,Ltd, in January 2025.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||